FOXF2 expression triggered by endocrine therapy orchestrates therapeutic resistance through reorganization of chromatin architecture in breast cancer
Cancer Letters · 2025
DOI: 10.1016/j.canlet.2025.217463 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Rui Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Canc…. Hauptthemen laut MEDLINE: Breast Neoplasms, Forkhead Transcription Factors, Drug Resistance, Neoplasm, Chromatin. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Patients with estrogen receptor-positive (ER+) breast cancer require long-term endocrine therapy. However, endocrine resistance remains a critical issue to be addressed. Herein, we show that ERα repressed FOXF2 transcription in ER+ breast cancer through facilitating H3K27me3 deposition around its genomic locus, therefore endocrine therapy triggered FOXF2 transcription via loss of H3K27me3. FOXF2 transactivation orchestrated endocrine resistance and bone metastasis. Mechanistically, FOXF2 acted as a pioneer factor to globally activate enhancers of genes involved in epithelial-mesenchymal transition/epithelial-osteogenic transition, as well as super-enhancers of NCOA3 (a coactivator of FOXF2) and SP1 (an upstream transactivator of FOXF2) by recruitingSMARCC1 that mediates the reorganization of chromatin architecture. Additionally, FOXF2 expression levels in the tumors of ER+ breast cancer predicted response to endocrine therapeutic drugs and the outcome of patients. Targeting BRD4, an essential transcriptional coactivator of FOXF2, significantly inhibited FOXF2-orchestrated endocrine resistance and bone metastasis. Our findings uncover a crucial mechanism underlying endocrine resistance and provide a promising strategy for managing endocrine-resistant breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Tianjin, 300060, China; Key Laboratory of Breast Cancer Prevention…
- Department of Biochemistry and Molecular Biology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Tianjin, 300060, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhang, R., Jiang, W. J., Zhao, S., Kang, L. J., Wang, Q. S., & Feng, Y. M. (2025). FOXF2 expression triggered by endocrine therapy orchestrates therapeutic resistance through reorganization of chromatin architecture in breast cancer. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.217463
Vancouver
Zhang R, Jiang WJ, Zhao S, Kang LJ, Wang QS, Feng YM. FOXF2 expression triggered by endocrine therapy orchestrates therapeutic resistance through reorganization of chromatin architecture in breast cancer. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.217463
BibTeX
@article{Zhang2025,
author = {Zhang, Rui and Jiang, Wen-Jing and Zhao, Shuai and Kang, Li-Juan and Wang, Qing-Shan and Feng, Yu-Mei},
title = {FOXF2 expression triggered by endocrine therapy orchestrates therapeutic resistance through reorganization of chromatin architecture in breast cancer},
journal = {Cancer Letters},
year = {2025},
doi = {10.1016/j.canlet.2025.217463}
}
EUVIMED